Trump Calls for 10% Credit Card Interest Rate Cap Starting 2026 
Stellantis to End Plug-In Hybrid Sales in the U.S. as Demand Shifts Toward Traditional Hybrids 
Nvidia Appoints Former Google Executive Alison Wagonfeld as First Chief Marketing Officer 
Supreme Court to Hear Cisco Appeal on Alien Tort Statute and Human Rights Liability 
FTC Blocks Edwards Lifesciences’ JenaValve Acquisition in Major Antitrust Ruling 
Chevron Seeks Expanded U.S. License to Boost Venezuelan Oil Exports Amid Sanctions Talks 
Ford Targets Level 3 Autonomous Driving by 2028 with New EV Platform and AI Innovations 
OpenAI Sets $50 Billion Stock Grant Pool, Boosting Employee Equity and Valuation Outlook 
FCC Exempts Select Foreign-Made Drones From U.S. Import Ban Until 2026 
Walmart to Join Nasdaq-100 Index as It Replaces AstraZeneca Following Exchange Move 
Johnson & Johnson Secures Tariff Exemption by Agreeing to Lower Drug Prices in the U.S. 
BlueScope Steel Shares Slip After Board Rejects A$13.2 Billion Takeover Bid 
Trump Pushes $100 Billion U.S. Oil Investment Plan for Venezuela After Maduro Seizure 
Samsung Forecasts Strong Q4 Profit on AI-Driven Memory Chip Boom 
AustralianSuper Backs BlueScope Steel’s Rejection of $9 Billion Takeover Bid 
Boeing 737 MAX 10 Advances in FAA Testing as Certification Delays Continue 
WALTHAM, Mass., March 17, 2017 -- Proteon Therapeutics Inc. (Nasdaq:PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients with kidney and vascular diseases, today announced that Company management will present at the Oppenheimer 27th Annual Healthcare Conference in New York City on Wednesday, March 22, 2017 at 1:35 p.m. ET.
A live audio webcast of the presentation can be accessed by visiting the Investor and Media section of the Company’s website at www.proteontherapeutics.com. A replay of the webcast will be archived on the Proteon website following the presentation.
About Proteon Therapeutics
Proteon Therapeutics is committed to improving the health of patients with kidney and vascular diseases through the development of novel, first-in-class therapeutics. Proteon's lead product candidate, vonapanitase, is an investigational drug intended to improve hemodialysis vascular access outcomes. Proteon is currently enrolling patients in PATENCY-2, a Phase 3 clinical trial evaluating vonapanitase in patients with chronic kidney disease (CKD) undergoing surgical creation of a radiocephalic arteriovenous fistula for hemodialysis. Proteon is also evaluating vonapanitase in a Phase 1 clinical trial in patients with peripheral artery disease (PAD). For more information, please visit www.proteontx.com.
Investor Contact
George Eldridge, Proteon Therapeutics, Senior Vice President and Chief Financial Officer
781-890-0102
[email protected]
Media Contact
Ann Stanesa, Ten Bridge Communications
617-230-0347
[email protected]
